Spots Global Cancer Trial Database for S 81694 Plus Paclitaxel in Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: S 81694 Plus Paclitaxel in Metastatic Breast Cancer
Official Title: Phase I/II Trial of S 81694 Administered Intravenously in Combination With Paclitaxel to Evaluate the Safety, Pharmacokinetic and Efficacy in Metastatic Breast Cancer
Study ID: NCT03411161
Study Description
Brief Summary: The purpose of this study is to determine the safety profile, the maximum tolerated dose (MTD) and the associated dose-limiting toxicities (DLTs) of S 81694 in combination with paclitaxel in metastatic breast cancer (mBC) patients, and to investigate the antitumour activity of the combination in metastatic triple negative breast cancer (mTNBC) patients.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Institut Jules Bordet Clinique Oncologie Médicale, Bruxelles, , Belgium
UZ Leuven Campus Gasthuisberg Dept. of General Medical, Leuven, , Belgium
Institut de Cancérologie de l'Ouest site Saint Herblain, Saint Herblain, , France
Chiba cancer center Breast surgery, Chiba, , Japan
Osaka International Cancer Institute, Osaka, , Japan
Erasmus MC Section Clinical Pharmacology, Rotterdam, , Netherlands
Contact Details
Name: Mario CAMPONE, Pr
Affiliation: Institut de Cancérologie de l'Ouest site Saint Herblain
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
